S2 Table. Characteristics of patients with stage III NSCLC

Characteristic	Age ≥ 80 yr	Age < 80 yr	p-value
No. of patients	126	1,064	
Male	100 (78.7)	889 (83.6)	0.172
Ever-smoker	89 (70.6)	831 (78.9)	0.034
BMI	22.05±3.39	22.97±3.41	0.006
Histopathology			
Squamous cell carcinoma	68 (53.5)	577 (54.2)	0.883
Adenocarcinoma	42 (33.1)	399 (37.5)	0.329
Large cell carcinoma	1 (0.8)	6 (0.6)	0.755
NSCLC NOS	6 (4.7)	57 (5.4)	0.763
Performance status			
0, 1	52 (68.4)	737 (90.0)	< 0.001
2, 3, 4	24 (31.6)	82 (10.0)	< 0.001
Pulmonary function			
FEV_1 % predicted	78.74±26.96	73.92±22.11	0.057
FVC % predicted	74.14±20.77	79.08±20.13	0.029
Initial treatment of NSCLC			
Surgery	9 (7.1)	184 (17.3)	0.003
Surgery only	7 (5.5)	111 (10.4)	0.079
Surgery and adjuvant therapy	2 (1.6)	73 (6.9)	0.020
Chemotherapy	15 (11.8)	245 (23.0)	0.004
RT only	30 (23.6)	70 (6.6)	< 0.001
CCRT	8 (6.3)	310 (29.1)	< 0.001
Best supportive care	55 (43.3)	203 (19.1)	< 0.001

Values are presented as number (%) or mean±SD. BMI, body mass index; CCRT, concurrent chemo-radiation therapy; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; RT, radiation therapy; SD, standard deviation.